Fig. 2.

MSTN mRNA but not pre-mRNA levels are increased by dexamethasone (Dex) treatment. A: gel demonstrating the expression pattern of MSTN mRNA, MSTN pre-mRNA, and GAPDH from TA muscles from 3 vehicle-injected and 3 Dex-injected mice. All images were taken at the same intensity. Cont, control. B: gel demonstrating the expression pattern of MSTN mRNA, MSTN pre-mRNA, and GAPDH from TA muscles from 3 vehicle-treated and 3 Dex-treated plates of C₂C₁₂ myotubes. All images were taken at the same intensity. C: quantification of MSTN mRNA levels relative to GAPDH levels for vehicle and Dex-injected mice. The bars represent means ± SE for n = 4 vehicle-injected and n = 5 Dex-injected mice. *Significantly different from vehicle injected, P < 0.05. D: quantification of MSTN pre-mRNA levels relative to GAPDH levels for vehicle and Dex-injected mice. The bars represent means ± SE for n = 4 vehicle-injected and n = 5 Dex-injected mice. *Significantly different from vehicle injected, P < 0.05. E: quantification of MSTN mRNA levels relative to GAPDH levels for vehicle and Dex-treated C₂C₁₂ myotubes. The bars represent means ± SE for n = 4 different experiments. *Significantly different from vehicle treated, P < 0.05. F: quantification of MSTN pre-mRNA levels relative to GAPDH levels for vehicle and Dex-treated C₂C₁₂ myotubes. The bars represent means ± SE for n = 4 different experiments. *Significantly different from vehicle treated, P < 0.05.